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Abstract
Background Breast cancer development and progression are
dependent on estrogen activity. In premenopausal women,
estrogen production is mainly regulated through the
hypothalamic-pituitary-gonadal (HPG) axis.
Methods We have investigated the prognostic significance of
two variants of genes involved in the HPG-axis, the GnRH
(encoding gonadotropin-releasing hormone) 16Trp/Ser
genotype and the LHR  (encoding the luteinizing hormone
receptor)  insLQ  variant, in retrospectively collected
premenopausal breast cancer patients with a long follow-up
(median follow-up of 11 years for living patients).
Results Carriership was not related with breast cancer risk (the
case control study encompassed 278 premenopausal cases
and 1,758 premenopausal controls). A significant adverse
relationship of the LHR insLQ and GnRH 16Ser genotype with
disease free survival (DFS) was observed in premenopausal
(hormone receptor positive) breast cancer patients. In particular,
those patients carrying both the GnRH 16Ser and LHR insLQ
allele (approximately 25%) showed a significant increased risk
of relapse, which was independent of traditional prognostic
factors (hazard ratio 2.14; 95% confidence interval 1.32 to
3.45; P = 0.002).
Conclusion We conclude that the LHR insLQ and  GnRH
16Ser alleles are independently associated with shorter DFS in
premenopausal patients. When validated, these findings may
provide a lead in the development of tailored treatment for
breast cancer patients carrying both polymorphisms.
Introduction
The diagnosis of breast cancer is made one million times each
year worldwide. About one-quarter of these women are pre-
menopausal at time of diagnosis, which is associated with
poor prognosis compared to postmenopausal women [1,2]. It
is anticipated that, as a result of changing demographic and
lifestyle factors, more and more women will be diagnosed at a
younger age with breast cancer [3,4]. In addition to age and
family history, several factors relating to increased or pro-
longed cumulative estrogen exposure have been identified as
important risk factors for breast cancer development and pro-
gression [5,6]. Polymorphic variation in genes regulating
estrogen production may partly explain differences in suscep-
tibility, clinical presentation and outcome of breast cancer
between individuals or populations [6,7].
In premenopausal women, estrogens predominantly arise from
the ovaries, where production is regulated by the neuro-endo-
crine system consisting of hypothalamus, pituitary and
gonads: the HPG axis. Internal and external stimuli are inte-
grated in the brain, resulting in the pulsatile secretion of the
hypothalamic neuropeptide gonadotropin-releasing hormone
(GnRH). GnRH reaches the gonadotroph cells in the anterior
pituitary through the hypophysial portal circulation, where it
stimulates de novo synthesis and secretion of the gonadotro-
pins follicle stimulating hormone and luteinizing hormone (LH),
CI = confidence interval; df = degrees of freedom; DFS = disease free survival; ER = estrogen receptor; GnRH = gonadotropin-releasing hormone; 
HPG = hypothalamic-pituitary-gonadal; HR = hazard ratio; HWE = Hardy-Weinberg equilibrium; insLQ = insertion Leu-Gln; LH = luteinizing hormone; 
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which reach the ovaries in women through the circulation. LH,
acting through the LH receptor (LHR), stimulates production
of androgen precursors in theca cells that surround antral fol-
licles. Follicle stimulating hormone subsequently regulates the
granulosa cell enzyme aromatase, which converts these
androgens to estrogens. In turn, ovarian sex steroid and pep-
tide hormones (inhibin A and B) provide negative feedback
regulation, either in the pituitary or hypothalamus. The meno-
pausal transition, that is, the cessation of menstrual cycling, is
characterized by disruption of this tightly balanced HPG axis
system and is accompanied by continuously increased serum
LH and follicle stimulating hormone in combination with
decreased levels of ovarian sex steroid hormones [8,9].
We have previously reported, in a training set of 266 Austral-
ian breast cancer patients, an association between a common
polymorphic CTCCAG (Leu-Gln (LQ)) insertion (LHR insLQ)
in the signal peptide of the LHR gene and poor survival [10].
No associations between its ligand, LH, genotype and clinical
parameters were observed in this study. In our subsequent val-
idation study on a large independent breast cancer cohort of
751 retrospectively collected Dutch patients with long
detailed follow-up, we have confirmed the association of the
LHR insLQ gene variant with a shorter disease-free survival
(DFS) [11]. Furthermore, we have shown the functional impor-
tance of the LQ insertion in the signal peptide, that is, an
increased activity for the LHR insLQ variant compared with the
LHR non-LQ protein. We hypothesized an ovary-dependent
increase in cumulative estrogen exposure that may influence
breast cancer outcome in patients with the LHR insLQ geno-
type [10]. Interestingly, the GnRH gene also carries a common
signal peptide polymorphism (Trp16Ser) [12], which has been
associated with altered bone mineral density, an indirect
marker for estrogen exposure [13].
In line with the hypothesis that possible associations of the
above mentioned polymorphisms with outcome would depend
on HPG-regulation of ovarian function, we have investigated
associations of the LHR insLQ and GnRH 16Ser alleles with
premenopausal breast cancer outcome in the present study.
We observed that hormone receptor positive premenopausal
women carrying either of the variant alleles or the combined
variant alleles of both genes had a significant shorter DFS;
LHR insLQ and the combined alleles were independent of tra-
ditional prognostic factors.
Materials and methods
Breast tumor samples
The study design was approved by the Medical Ethics Com-
mittee of the Erasmus MC, Rotterdam, the Netherlands. From
the DNA samples with complete follow up described previ-
ously [11], we have included 278 premenopausal patients
with known estrogen receptor (ER) status, conclusive geno-
types and complete follow up. All tumors were invasive (42
had an additional in situ component).
The menopausal status of patients was determined according
to the guidelines of the European Organization of Research
and Treatment of Cancer (EORTC). The median age of
patients at diagnosis was 45 years (range 22 to 57 years). The
median follow-up period of all patients was 112 months (range
9 to 255 months) and of still living patients 130 months from
primary surgery (range 13 to 255 months). Pathological exam-
ination was not performed centrally and reflects daily practice
in the various participating regional hospitals as described
previously. Other patient characteristics are listed in Table 1.
Control population
As a control cohort we studied banked blood samples of pre-
and perimenopausal women from the Eindhoven Perimeno-
pausal Osteoporosis Study (EPOS). The EPOS study is a
population-based cohort study of pre-, peri- and postmeno-
pausal women born between 1941 and 1947 living in the city
of Eindhoven, The Netherlands (median age 50.0 years (range
46 to 57 years)). The study rationale and design have been
described previously [14]. Participants gave their written
informed consent, and the study was approved by the Medical
Ethics Committee of the Erasmus MC, Rotterdam. For the
present study we included 1,758 (successful genotyping for
the LHR as well as GnRH genotypes) pre- and perimenopau-
sal subjects, after excluding women with a history of breast
carcinoma. All subjects (median age 49.5 years) are of Cauca-
sian Dutch descent. Data for baseline examination and blood
samples for extracting DNA from peripheral leucocytes were
collected between 1994 and 1995.
Genotyping
High molecular weight genomic DNA was used as a template
for PCR amplification. Exon 1 of the LHR gene was amplified
as described by Atger and colleagues [15] using a 5'-hex-
achlorofluorescein labeled forward primer. Separation and siz-
ing of the PCR fragments and assignment of LHR insLQ
genotype was performed using the ABI Prism 3100 auto-
mated capillary DNA sequencer and Genescan and Genoty-
per software packages (Applied Biosystems, Perkin Elmer,
Nieuwerkerk aan den IJssel, The Netherlands) as described by
us before [11].
The 16Trp/Ser polymorphism in the GnRH gene was deter-
mined using the Taqman allelic discrimination assay. Primer
sequences used for amplification of the fragment of exon 1,
including the single nucleotide polymorphism (SNP) were
AATTCAAAAACTCCTAGCTGGCCTTA (forward) and CAT-
AGGACCAGTGCTGGCT (reverse). Used probes (with SNP
underlined) were 5'-VIC-CACGCACCAAGTCA (anti-sense)
and 5'-FAM-AGCCACGAAGTCA (anti-sense). Primer and
probe sequences were optimized using the SNP assay-by-
design service of Applied Biosystems (for details, see [16]).Available online http://breast-cancer-research.com/content/9/4/R51
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These reactions were performed on the Taqman Prism 7900
HT 384 wells format. Snap frozen primary breast cancer spec-
imens, stored in liquid nitrogen and from which the DNA was
obtained for genotyping, contain a relatively high proportion
(>40%) of non-tumor tissue. This ensures accurate genotyp-
ing, irrespective of the possible loss of heterozygosity that may
occur in tumor tissue [10]. Furthermore, to test for possible
loss of heterozygosity we have examined the Hardy-Weinberg
equilibrium (HWE).
Table 1
Baseline characteristics in 278 premenopausal patients according to LHR insLQ and GnRH 16Ser carriership
LHR insLQ GnRH 16Ser
Feature Number 
(percent)
Non-carriers 
(percent)
Carriers 
(percent)a
P valuea Non-carriers 
(percent)
Carriers 
(percent)
P valuea
Breast cancer cases 278 (100) 147 (53) 131 (47) 157 (56) 121 (44)
Age in years 0.18 0.56
<35 19 (7) 12 7 9 10
35–39 35 (12) 13 22 17 18
40–49 167 (60) 93 74 99 68
50–59 57 (21) 29 28 32 25
Node status 0.78 0.001b
Negative 134 (48) 72 62 89 45
Positive 144 (52) 75 69 68 76
Histological gradec
0.04 0.15
Well/mod 66 (24) 44 22 41 25
unknown 59 (21) 28 31 27 32
Poor 153 (55) 75 78 89 64
Tumor sized 0.58 0.30
≤2 cm 113 (41) 62 51 68 45
>2 cm 165 (59) 85 80 89 76
Estrogen receptor statusc,e 0.095 0.29
Negative 78 (28) 35 43 48 30
Positive 200 (72) 112 88 109 91
Progesterone receptor statusc,e 0.15 0.54f
Negative 70 (25) 32 38 42 28
Positive 199 (72) 111 88 111 88
HER2 amplifiedc 0.68 0.85
Yes 55 (20) 28 27 30 25
No 202 (73) 106 96 114 88
Adjuvant therapy 0.54 0.09
No 158 (57) 88 70 96 62
Hormonal 4 (1) 1 3 1 3
Chemotherapy 110 (40) 55 55 55 55
Combined 6 (2) 3 3 5 1
aχ2 test. bAlso, when stratified per 'genotype', P = 0.003. cNumbers in cells may not add up due to incomplete information on histological grade 
and/or receptor status. dTumors of unknown size (n = 10) are included as tumor size >2 cm. eThe cutoff value used was 10 fmol/mg protein. 
fSignificant when stratified per 'genotype', P = 0.02. Entries in bold represent significant outcomes.Breast Cancer Research    Vol 9 No 4    Piersma et al.
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Statistical analysis
Pearson's χ2 analysis and Fisher's exact test were used to test
for independence of the alleles (HWE) and for association
analyses with patient and tumor characteristics, respectively.
We allowed for three possible genetic models to explain differ-
ences in patient and tumor characteristics between genotype
groups: linear, dominant or recessive effects. A linear effect,
assuming a dose-response relationship of the association for
the presence of zero, one or two copies of the allele, was
tested using a (χ2) linear trend analysis [17]. A dominant effect
between hetero- and homozygous combined carriers versus
non-carriers was tested using χ2  analysis. Indications for
recessive effects were not observed. Univariate and multivari-
ate DFS analyses (endpoint: recurrence excluding second pri-
mary breast tumor) were carried out using Cox proportional
hazards regression analysis. Hazard ratios (HRs) for the LHR
insLQ and GnRH 16Ser alleles are presented with their 95%
confidence interval (CI). Differences between HRs per LHR
insLQ and GnRH 16Ser genotype were tested using the like-
lihood ratio test associated with the Cox regression analysis.
In multivariate analysis, Cox proportional hazard models for
DFS were applied to test the genotype variables against tradi-
tional factors using a forward stepwise model. The multivariate
model included age, positive versus negative nodal status, dif-
ferentiation grade, tumor size (larger tumors versus tumors ≤2
cm), ER status and adjuvant therapy. DFS curves were gener-
ated using the actuarial method of Kaplan-Meier [18] and log-
rank tests were used to test for equality of survival functions.
All computations were carried out using the STATA statistical
package, version 9.2 (Stata Corp., College Station, TX, USA).
Statistical significance was assumed at P ≤ 0.05; P values are
two-tailed and relate to data during the total period of follow-
up.
Results
LHR insLQ and GnRH 16Trp/Ser genotyping
Genotype analysis for the LHR insLQ polymorphism in the
278 premenopausal patients studied revealed an allele fre-
quency of 0.27. This resulted in 147 (52.9%) nonLQ/nonLQ
homozygotes, 113 (40.7%) heterozygotes and 18 (6.5%)
insLQ/insLQ homozygotes. The allele frequency for the GnRH
16Ser polymorphism was 0.25. The genotype distribution was
157 (56.5%) 16Trp/16Trp homozygotes, 103 (37.1%) heter-
ozygotes and 18 (6.5%) 16Ser/16Ser  homozygotes. Both
genotypes were found to be in HWE (P = 0.55 and P = 0.84,
respectively). The genotype distributions and allele frequen-
cies in the control cohort from the EPOS study (n = 1,758),
did not differ significantly from the case distributions. Geno-
type results for the LHR insLQ polymorphism revealed an
allele frequency of 0.29. The genotype distribution was 901
(51.3%) nonLQ/nonLQ homozygotes, 708 (40.3%) heterozy-
gotes and 149 (8.5%) insLQ/insLQ homozygotes. Genotyp-
ing for the GnRH 16Ser allele resulted in an allele frequency
of 0.25 and revealed 1,004 (57.1%) 16Trp/16Trp homozy-
gotes, 627 (35.7%) heterozygotes and 127 (7.2%) 16Ser/
16Ser homozygotes, in HWE. All genotype frequencies and
allele frequencies are closely similar in the cases series and in
the population controls, which lends support to the genotyp-
ing results in tumor material. We conclude that neither LHR
insLQ nor GnRH 16Ser genotypes influence the risk of breast
cancer development.
Associations with patient and tumor characteristics
The distribution of clinico-pathological characteristics across
the GnRH 16Trp/Ser genotype showed a dominant effect of
presence of the GnRH 16Ser allele. Carriers of the GnRH
16Ser allele were, therefore, compared to non-carriers. Carri-
ership of the GnRH 16Ser allele was significantly associated
with increased lymph node involvement (P = 0.001), while
GnRH genotype was associated with progesterone receptor
levels (P = 0.02). LHR insLQ was associated with histological
grade. Both polymorphisms were not significantly associated
with other clinico-pathological characteristics. No significant
interaction between the presence of the LHR insLQ and
GnRH 16Ser variants was observed in these association
analyses.
Associations of LHR insLQ and GnRH 16Ser variants 
with DFS
We hypothesized that HPG-mediated increases in cumulative
ovarian estrogen exposure influence breast cancer outcome.
The adverse association of the LHR insLQ allele with DFS
was observed in the premenopausal patients (HR for carriers
versus non-carriers = 1.59, 95% CI 1.14 to 2.23, P = 0.007;
Table 2). In these premenopausal patients the LHR insLQ
genotype was an independent prognostic factor: addition of
LHR insLQ carriership to the multivariate model resulted in an
increase of χ2 from 44.06 to 52.23 (Δχ2 = 8.17 (df = 1), P =
0.004) for DFS. The association between the presence of the
GnRH 16Ser allele and DFS was also tested. An increased
HR of 1.40 (95% CI 1.00 to 1.96, P = 0.05; Table 2) for
GnRH 16Ser carriers versus non-carriers was observed.
Interestingly, in the biological relevant hormone receptor sub-
group (ER and/or progesterone receptor positive, n = 225
(81%)), the LHR insLQ genotype retained significance. The
adverse association of the LHR insLQ allele with DFS had a
HR for carriers versus non-carriers of 1.59 (95% CI 1.11 to
2.28, P = 0.012). It was also an independent prognostic fac-
tor: addition of LHR insLQ carriership to the multivariate
model resulted in an increase of χ2 from 36.28 to 42.70 (Δχ2
= 6.42 (df = 1), P = 0.01) for DFS. Moreover, the association
between the presence of the GnRH 16Ser allele and DFS
revealed a significantly increased HR of 1.44 (95% CI 1.01 to
2.07, P = 0.046). In multivariate analysis for GnRH 16Ser car-
riers versus non-carriers this was not significant.
Cooperative effect of variants on the HPG axis and DFS
The HPG system in the premenopausal woman involves a
c o o p e r a t i v e  e f f e c t  o f  b o t h  G n R H  a n d  L H  a c t i o n  o n  t h eAvailable online http://breast-cancer-research.com/content/9/4/R51
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regulation of ovarian sex steroid production. Therefore, we
have examined in an exploratory study the combined effect of
the GnRH 16Ser and LHR insLQ variants in these premeno-
pausal breast cancer patients. We combined heterozygous
and homozygous carriers, providing four groups of similar
sizes. Non-carriers, carriers of the GnRH 16Ser allele, carriers
of the LHR insLQ allele, and carriers of both alleles were
compared.
The combination of both variants in premenopausal breast
cancer patients, present in 22% of this group, resulted in a HR
of 2.17 versus non-carriers of both variants (95% CI 1.36 to
3.48, P = 0.001; log-rank test for trend P = 0.001; Figure 1a
Table 2
Cox univariate and multivariate analysis for disease free survival in the 278 premenopausal breast cancer patients
Patients Univariate analysis Multivariate analysis
Factor of base model Number Percent HR 95 percent CI P value HR 95 percent CI P value
Age (years)
<39 54 24 1.00 1.00
40–49 167 60 0.72 0.50–1.06 0.66 0.44–0.98
50–59 57 21 0.42 0.23–0.77 0.013 0.35 0.19–0.67 <0.001
Nodal status
Negative 134 48 1.00 1.00
Positive 144 52 1.90 1.34–2.70 <0.001 3.68 2.11–6.42 <0.001
Histological grade
Poor 153 55 1.00 1.00
Unknown 59 21 0.51 0.32–0.83 0.54 0.33–0.88
Well/moderate 66 24 0.55 0.36–0.85 0.002 0.56 0.35–0.88 0.019
Tumor size
≤2 cm 113 41 1.00 1.00
>2 cm 165 59 1.77 1.23–2.54 0.002 1.57 1.07–2.30 0.021
Estrogen receptor status
Negative 78 28 1.00 1.00
Positive 200 72 0.87 0.60–1.27 0.48 1.01 0.68–1.49 0.96
Adjuvant therapy
No 158 57 1.00 1.00
Yesa 120 43 1.41 1.01–1.97 0.045 0.41 0.24–0.70 0.001
Factors analyzed
Carriership
Non-carriersb 1.00 1.00
GnRH 16Ser 121 44 1.40 1.00–1.96 0.050 1.32 0.93–1.88 0.12
LHR insLQ 131 47 1.59 1.14–2.23 0.007 1.64 1.16–2.32 0.005
Combined carriership
Non-carriers 87 31 1.00 1.00
Only GnRH 16Ser 60 22 1.39 0.84–2.29 0.19 1.24 0.74–2.08 0.42
Only LHR insLQ 70 25 1.59 0.99–2.54 0.055 1.56 0.97–2.51 0.067
LHR insLQ+GnRH16Ser 61 22 2.17 1.36–3.48 0.001 2.14 1.32–3.45 0.002
aOf 120 patients who received adjuvant therapy, 110 received chemotherapy (mainly CMF, n = 101), 4 endocrine therapy, and 6 both; node 
negatives were not treated. bThe number of GnRH 16Ser non-carriers was 157, and of LHR insLQ non-carriers was 147 patients.Breast Cancer Research    Vol 9 No 4    Piersma et al.
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and Table 2). This HR is higher than that for HER2 amplified
tumors (HR of 1.61, 95% CI 1.09 to 2.39, P = 0.016); HER2
is amplified in about 20% of the tumors. In multivariate analy-
sis, including the prognostic factors age, nodal status, differ-
entiation grade, tumor size, ER status, and adjuvant therapy,
the association was independent: Δχ2 = 10.0 (df = 3), P =
0.018; HR = 2.14, 95% CI 1.32 to 3.45, P = 0.002. No sig-
nificant interaction between the presence of the LHR insLQ
and  GnRH 16Ser variants was observed in these survival
analyses.
We next studied the effect in hormone receptor positive
patients. The combination of both variants, present in 52 out
of 225 patients of this group, resulted in a HR of 2.43 versus
non-carriers of both variants (95% CI 1.42 to 4.18, P  =
0.0013; log-rank test for trend P = 0.0055; Figure 1b). In mul-
tivariate analysis, including the prognostic factors listed above,
the association was independent: Δχ2 = 8.72 (df = 3), P =
0.03; HR = 2.06, 95% CI 1.21 to 3.49, P = 0.007. No signif-
icant interaction between the presence of the LHR insLQ and
GnRH 16Ser variants was observed in these survival
analyses.
Discussion
Breast cancer is a heterogeneous and complex disease. Many
gene variants, acting in concert with each other and with envi-
ronmental factors, may influence its susceptibility, prognosis
and response to treatment [19]. In light of their possible role in
the variability of estrogen exposure, variants of genes involved
in the HPG axis are likely candidates to contribute to differ-
ences in clinical phenotype and outcome. In the present study
we tested this hypothesis. In a genetic association approach
we used stratification for ovarian activity and explored cooper-
ative action of two HPG gene variants. We show an associa-
tion between the LHR insLQ allele and shorter DFS in
premenopausal patients, especially in the hormone receptor
positive subset. A common GnRH gene variant, GnRH 16Ser,
showed an association with lymph node involvement. In addi-
tion, coincident carriership of the GnRH 16Ser and  LHR
insLQ variants, present in almost one-quarter of the patients,
resulted in a more than doubled risk of recurrence of disease
in (hormone receptor positive) premenopausal patients with a
long (>10 years follow-up of still living patients). Multivariate
analyses showed that these associations with poor DFS were
independent of known prognostic factors.
Whether variants of the GnRH gene differ in function remains
to be elucidated. Substitution of Trp16 by the less hydropho-
bic serine may change the efficiency of the GnRH signal pep-
tide. Using the same in vitro assay for the insLQ signal peptide
variant, as described by us previously [11], we were unable to
detect a difference in signal peptide efficiency between the
GnRH 16Ser and GnRH 16Trp signal peptide constructs
(data not shown). Furthermore, in silico analysis of the variants
using the program SignalP 3.0 [20] did not result in any differ-
ence in signal peptide characteristics. On the other hand, Iwa-
saki and colleagues [13] have described an association
between the GnRH 16Trp allele and higher bone mineral den-
sity, considered to be an indirect marker for estrogen activity,
in 384 Japanese postmenopausal women; this suggests there
is higher estrogen activity in women bearing this variant. In
contrast, we observed a significant increased lymph node
involvement and shorter DFS in Caucasian breast cancer
patients carrying the other variant, the GnRH 16Ser allele,
which we hypothesize to result from a higher level of cumula-
tive estrogen exposure. Possible reasons for the apparent
Figure 1
Relation of GnRH and LHR gene variants with disease-free survival Relation of GnRH and LHR gene variants with disease-free survival. (a) 
Kaplan-Meier curves for disease free survival (DFS) comparing carriers 
versus non-carriers in all premenopausal breast cancer patients. DFS 
curves are depicted for carriers of LHR insLQ (blue), GnRH 16Ser 
(green) and both variants (red) versus non-carriers of both variants 
(gray dotted line). (b) Kaplan-Meier curves for DFS comparing carriers 
versus non-carriers in hormone receptor positive premenopausal breast 
cancer patients. DFS curves are depicted for carriers of LHR insLQ 
(blue), GnRH 16Ser (green) and both variants (red) versus non-carriers 
of both variants (gray dotted line).Available online http://breast-cancer-research.com/content/9/4/R51
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conflicting results are numerous, including differences in sam-
ple size, technical approach, and ethnicity, or so far unknown
differences in the interaction of genetic and environmental fac-
tors between Japanese and Caucasian subjects. Conse-
quently, further studies are needed to identify the exact
mechanisms of the effect of the GnRH 16Ser polymorphism,
including linkage to other polymorphisms in the GnRH gene
that may affect regulation of expression.
There are several hypotheses as to how GnRH and LHR gene
variants may affect tumor features and clinical outcome in
breast cancer as demonstrated in this study. In view of the
abundant data on the direct effects of GnRH modulation on
sex steroid hormone-dependent cancers, a direct effect of
locally produced GnRH via GnRH receptors expressed in
breast cancer tissue cannot be ruled out [21-24]. Local co-
expression of mRNAs for GnRH and the GnRH receptor in
breast cancer tissue has been shown [25,26], and direct
growth inhibition of cultured breast cancer cells have been
reported as well [27]. However, to our knowledge, local pro-
duction of GnRH has not been shown. Hypothalamic GnRH is
unlikely to reach the breast via the peripheral circulation given
its low concentration and short half-life [28]. Furthermore, the
effects of GnRH agonist treatment regimens are most likely
explained by down-regulation of pituitary GnRH receptors and
subsequent shutdown of the HPG axis [29]. A few studies
have shown LHR expression in normal and breast tumor cells.
However, it is less likely that direct effects of LH explain the
adverse association of LHR insLQ with DFS, since this was
not seen in the postmenopausal patients (data not shown) in
whom circulating LH levels are high.
In premenopausal women, epithelial proliferation in the non-
pregnant, non-lactating breast is maximal approximately one
week after ovulation in the luteal phase of the menstrual cycle.
During the luteal phase, which can be considered a risky
period for carcinogenesis in the breast, the corpus luteum is
the main site of estrogen and progesterone hormone produc-
tion, which is, in large part, dependent on LHR action. There-
fore, increased cyclic hormonal stimulation of early breast
cancer in women carrying activating HPG gene variants may
enhance dedifferentiation and worsen prognosis. In premeno-
pausal breast cancer patients with advanced disease, reduc-
tion of estrogen levels by a GnRH agonist in combination with
the ER antagonist tamoxifen improves clinical outcome com-
pared with the use of GnRH agonists or tamoxifen alone
[29,30]. Randomized trials assessing whether the combina-
tion of a GnRH agonist with an aromatase inhibitor as adjuvant
therapy improves outcome compared to treatment consisting
of a GnRH agonist and tamoxifen are ongoing [31]. Regimens
for endocrine therapy are still largely empirically based [32].
Recently, it has been suggested that, as for adjuvant systemic
therapy, the role of genetic factors in breast cancer treatment
outcome should be considered [33]. Our current study identi-
fied almost 25% of premenopausal patients with a genetic
background associated with clearly significant poor outcome
and hypothetically associated with altered treatment out-
comes. Exploratory studies in our subset of patients that
received adjuvant endocrine therapy (n = 4) were too under-
powered to detect differences in response. Finally, it can be
hypothesized that the GnRH and LHR variants may play a role
in chemotherapy-induced amennorhoea [33], since 110 of the
patients studied were treated with chemotherapy. Although
adjuvant chemotherapy was equally divided over patients with
and without polymorphisms, possible differences in the
chance of ovarian failure resulting from chemotherapy may
bias the outcome. However, since chemotherapy is likely to
inhibit ovarian activity, this is not anticipated.
Conclusion
We have shown a strong and independent association with
DFS (HR = 2.1) in almost one-quarter of (hormone receptor
positive) premenopausal women carrying LHR insLQ and
GnRH 16Ser genotypes. The observations strongly suggest
that the adverse outcome in patients with these variants
occurs through enhanced HPG-mediated ovarian estrogen
production. Prospective studies, including serum estrogen
analyses, are needed. When validated in independent studies,
the observed results raise the possibility that LHR insLQ and
GnRH 16Ser genotyping may provide additional prognostic
information for premenopausal breast cancer patients in clini-
cal practice and may result in tailored endocrine treatments for
these patients.
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